lenalidomide / Generic mfg. - LARVOL DELTA

Effective front-line treatment of osteosclerotic myeloma with POEMS syndrome with daratumumab, lenalidomide and dexamethasone: a case report and literature review. (PubMed, Acta Clin Belg) - "Front-line treatment with daratumumab, lenalidomide, and dexamethasone (DRd) resulted in a rapid and durable clinical and biochemical response, including normalization of vascular endothelial growth factor levels. This improvement ultimately enabled the patient to successfully undergo ASCT.This case highlights the potential role of DRd as an effective induction strategy in functionally impaired patients with POEMS syndrome."

Journal • Endocrine Disorders • Hematological Malignancies • Monoclonal Gammopathy • Multiple Myeloma • Oncology • Pain • Rare Diseases • Transplantation

Real-world impact of high-risk cytogenetics and revised ISS (R2 ISS) on response and survival in multiple myeloma patients treated with various induction regimens: A single-center study from India. (ASH 2025) - "Bortezomib-based triplet regimens, including VRd (bortezomib, lenalidomide, dexamethasone) and VCD (bortezomib, cyclophosphamide, dexamethasone), remain the preferred choices for induction therapy in India...Financial constraints in the indian setting restrict access to novel agents like daratumumab, influencing therapy choices... In this Indian cohort, high-risk cytogenetics and advanced RAISS stages independently predicted poorer survival. R2-ISS offered superior prognostic value over R-ISS. Standard-risk patients had similar outcomes with VRd and VCD, while KRd showed promise in a limited group."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Real-world insights into multiple myeloma management: An analysis of EHR-derived data in the UK and Germany (ASH 2025) - "Most common first-line therapy was daratumumab, lenalidomide, and dexamethasone in Germany (13%), and cyclophosphamide, bortezomib, and dexamethasone (24%) in the UK. The UK and Germany cohorts included 616 and 466 patients, respectively. In both countries, 75% of patients were diagnosed at ISS stage II or III. Cytogenetic testing was reported for 59% of patients in Germany, compared to 60% of the UK cohort, with 1q21 gain/amplification and del13q being the most commonly reported positive tests in both countries."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China (ASH 2025) - P2 | "The DI-based regimens included DICd (C: cyclophosphamide; d: dexamethasone) plus vinorelbine (VDS), DId plus VDS, DId plus denosumab, DId plus venetoclax (VEN), DIPd (P: pomalidomide), DIR (R: lenalidomide), and DIRd plus VEN. Conclusion The DI-based regimen, as an initial treatment option for transplant-ineligible NDMM patients, demonstrates efficacy comparable to that observed in previous prospective randomized controlled trials (RCTs) (NCT03012880, NTR6297, ORR: 71–96%). This real-world study conducted in China further supports the promising efficacy and acceptable safety profile of the ixazomib plus daratumumab-based regimen as a first-line treatment for transplant-ineligible NDMM patients in routine clinical practice, including among elderly patients with multiple comorbidities."

Clinical • Real-world • Real-world evidence • Cardiovascular • CNS Disorders • Diabetes • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertension • Metabolic Disorders • Multiple Myeloma • Nephrology • Renal Disease • Transplantation • Vascular Neurology

Temporal trends in treatment patterns and overall survival for multiple myeloma management in Taiwan using the national health insurance claims database (ASH 2025) - "Since then, treatment for MM has continued to evolve, most notably with availability of anti-CD38 monoclonal antibodies such as daratumumab (D). We investigated temporal trends in MM treatment patterns and clinical outcomes from 2013 to 2022, a period encompassing onset of reimbursement for lenalidomide (R) in first line (1L) in patients with transplant-ineligible (TI) MM from February 2020, and D for second line (2L) and beyond from April 2020...Between study periods, VTd use in 1L (approximately 50% of patients) was unchanged, use of V(bortezomib)R-dexamethasone(d) increased from 0-17.59%, and use of regimens containing melphalan and alkylators decreased... The NHIRD provides health insurance for the whole population of Taiwan, allowing complete and longitudinal data collection across all treatment settings. We observed increased uptake of novel agents after their reimbursement under the National Health Insurance that coincided with a decrease in attrition rates and an..."

Claims database • Clinical • Reimbursement • US reimbursement • Hematological Malignancies • Multiple Myeloma

Real-world survey of triplet versus quadruplet regimen preferences in transplant-ineligible (TIE) or deferred patients with newly diagnosed (ND) multiple myeloma (MM) (ASH 2025) - P3 | "Recently, data pertaining to anti-CD38 mAb-containing quadruplet regimens have been published (IMROZ: isatuximab ± bortezomib, lenalidomide, and dexamethasone [Isa-VRd]; NCT03319667 and CEPHEUS: daratumumab ± bortezomib, lenalidomide, and dexamethasone [Dara-VRd]; NCT03652064). The real-world data shows that Dara-VRd has emerged as the preferred regimen for non-frail, TIE/deferred patients with ND MM and that DRd is the preferred regimen for frail, TIE patients with ND MM. While interest for Isa-VRd saw a drastic increase for frail TIE patients with ND MM following review of the data, Dara-VRd was still the preferred anti-CD38 regimen if quadruplet regimens were considered. Despite the lack of a subgroup analysis of frail versus non-frail patients from CEPHEUS, Dara-VRd remains the preferred quadruplet therapy over Isa-VRd for TIE/deferred ND MM."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Transplantation

Plasma cell leukemia: A single institution review of cases (ASH 2025) - "For salvage therapies, 4 patients received DCEP, 2 received PACE-based regimens, 1 patient achieved remission while on teclistamab, one had delayed ASCT (with third line therapy), and one received CAR-T therapy...There was no statistically significant difference in PFS1 (p = 0.86) or OS (p = 0.57) between patients who received conventional chemotherapy and those treated with a daratumumab-based quadruplet induction regimen. Of note, the majority of patients that received these quadruplet regimens did not receive lenalidomide or carfilzomib for induction of PCL. Although the results of this retrospective study showed that there was no significant difference in PFS1 and OS based on induction regimens, some patients received suboptimal regimens due to various constraints including prior treatment regimens, comorbidities, socioeconomic factors, and variabilities in access to care. Despite therapeutic advances in MM, PFS and OS in patients with both pPCL and sPCL remains..."

Clinical • Review • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Multiple Myeloma • Nephrology • Plasma Cell Leukemia • Renal Disease • RB1

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy (ASH 2025) - "Background: The University of Pittsburgh Medical Center (UPMC) partnered with IntegraConnect to conduct a quality initiative (QI) studying the utilization of anti-CD38 agents and quadruplet (quad) therapy (lenalidomide, CD38, proteasome inhibitor and dexamethasone) in newly diagnosed multiple myeloma (NDMM), and how treatment selection has evolved throughout the QI project to date. The QI implemented at UPMC for LOT 1 MM treatment led to an improvement in utilization of CD38 therapy, overall quad based therapy, and quad-based therapy among quad-eligible patients. Incorporation of physician focus group educational sessions further increased adherence to best practices. Additional follow-up is needed to evaluate sustainability and patient outcome."

Clinical • Hematological Malignancies • Multiple Myeloma

Racial disparities on incidence and survival in Mantle Cell Lymphoma: A surveillance, epidemiology and end results program database (2013-2022) retrospective analysis (ASH 2025) - "Since 2013, the therapeutic landscape for MCL has evolved with FDA approvals of novel treatments, including lenalidomide, Bruton tyrosine kinase inhibitors, and anti-CD19 chimeric antigen receptor T-cell therapy, aimed at improving patient outcomes... This large, population-based study reveals significant racial disparities in both incidence and survival of MCL, with non-Hispanic Black and Hispanic patients experiencing shorter survival compared to their non-Hispanic White counterparts. These findings underscore the impact of social determinants of health on cancer outcomes and highlight the urgent need for equitable access to advanced therapies. Further research is warranted to elucidate the mechanisms driving these disparities and to inform targeted interventions."

Retrospective data • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Baseline findings to inform quality improvement opportunities in low-risk Myelodysplastic Syndromes (ASH 2025) - "12.5% were treated with lenalidomide. 17.9% were treated with luspatercept... Baseline data from this multicenter QI initiative reveals variability in key diagnostic and treatment-related processes for low-risk MDS, with gaps noted in molecular testing, ESA workup, and iron overload monitoring. These findings highlight actionable targets for standardizing care and aligning with best practices. While post-intervention outcomes are pending, these results may guide other centers in identifying and addressing similar gaps to advance patient-centered care in low-risk MDS."

Hematological Malignancies • Myelodysplastic Syndrome

Physicians perceptions of fixed-duration epcoritamab + lenalidomide and rituximab regimens in relapsed/refractory follicular lymphoma: Insights from the epcore NHL-2 trial (ASH 2025) - "Before reviewing trial data, despite 40% reporting BsAb use, only 29% reported they would select BsAbs (i.e., mosunetuzumab, epcoritamab) as their preferred 3L regimen for a hypothetical patient with R/R FL (65-year-old male, stage III, and an ECOG PS of 1 who received R-CHOP in 1L and bendamustine + rituximab in 2L), and most respondents preferred CAR T therapy (42%) for this patient. U.S. oncologists demonstrated increased interest in the fixed duration of ER2 following review of EPCORE NHL-2 data, with a notable shift in preference from CAR T to BsAbs in earlier lines of treatment for R/R FL. The regimen's defined treatment duration and potential for use in 2L settings were key drivers of interest. These findings suggest that ER2 may offer a clinically attractive alternative to existing therapies, particularly for patients' ineligible for CAR T or those seeking outpatient, time-limited options."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Comprehensive cost analysis of 4th line + therapies for relapsed/refractory multiple myeloma in Germany: Drug, co-medication, and office-based treatment perspective (ASH 2025) - "Whilst there is no official myeloma registry in Germany, treatments we considered were reimbursable combination therapies frequently used in the 4 th line treatment of RRMM in Germany in 2023, containing: carfilzomib, daratumumab, elotuzumab, melflufen, selinexor, talquetamab and teclistamab, and newly approved therapeutic options like elranatamab, along with evidence-based recommendations regarding premedication, comedication, and mandatory prophylaxis of treatment-related adverse events, as outlined in the Summary of Product Characteristics (SmPC) and published literature... Costs for myeloma drugs and combinations show a broad variation, from 88.863€ for Elotuzumab/Revlimid/Dexamethasone (ERd), to 178.850€ for talquetamab treatment. The second lowest in terms of annual costs was melflufen with 106.839€, followed by Elotuzumab/Pomalidomide/Dexamethasone (EPd):119.301€, teclistamab: 124.626€, Selinexor/Dexamethasone (Sd): 129.976€, elranatamab: 146.706€ and..."

Cost-analysis • HEOR • Hematological Malignancies • Multiple Myeloma

Frequency of and finding risk factors for thromboembolism and major bleeding in patients with myelodysplastic syndrome undergoing allogeneic transplantation (ASH 2025) - "Four were on decitabine, 1 was on lenalidomide, and 1 was on azacitidine. Rates of TEE and bleed in MDS patients undergoing allo-SCT were similar and common at 26% and 22%, respectively. Bleeding, but not TEE, seemed to impact survival in line with one other report (Gergi et al. Blood 2024)."

Clinical • Acute Graft versus Host Disease • Cardiovascular • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Thrombosis • Transplantation

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

Etoposide +cytarabine plus G-CSF mitigates daratumumab-associated impairment on stem cell mobilization yields in multiple myeloma (ASH 2025) - "Objective: Quadruplet induction therapy comprising daratumumab(dara) and lenalidomide(lena), followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) has become the standard frontline treatment for patient with multiple myeloma(MM). The median total CD34+ cells collection was 19.33 × 10⁶/kg in the dara group, significantly lower than that in lena group (25.59 × 10⁶/kg, p=0.005). Notably, patients receiving more than eight doses of dara showed a reduced CD34+ cell collection (median 14.16 × 10⁶/kg vs. 21.45 × 10⁶/kg; p = 0.039)."

Hematological Disorders • Hematological Malignancies • Lymphoma • Multiple Myeloma • Neutropenia • CD34

High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma. (ASH 2025) - "Case Report We present the case of a female patient diagnosed with IgG multiple myeloma in 2015, initially treated with induction chemotherapy using lenalidomide, bortezomib, and dexamethasone (RVD), followed by autologous HSCT...She subsequently progressed on a combination of daratumumab, lenalidomide, and dexamethasone. Further disease progression occurred on a regimen of ixazomib, pomalidomide, and dexamethasone. She then achieved a temporary response to carfilzomib, lenalidomide, and dexamethasone, followed by a second autologous HSCT, but relapsed again after approximately one year of maintenance therapy...While this association warrants further investigation, it emphasizes the need for ongoing observation of patients who have received CAR T-cell therapy. Future studies should aim to clarify the potential mechanistic links, including clonal evolution, selective pressures imposed by immunotherapy, and the contribution of prior cytotoxic exposures."

IO biomarker • Acute Lymphocytic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Cardiomyopathy • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • TP53

CAR-T cell therapy in multiple myeloma in a front-line setting: A systematic review and meta-analysis (ASH 2025) - "Induction therapy regimen before CAR-T included bortezomib, lenalidomide, and dexamethasone (VRd), or clarithromycin, lenalidomide, and dexamethasone (BiRd), or a combination of VRd and bortezomib, doxorubicin, and dexamethasone (PAD). CAR-T cell therapy showed promising rates of overall response and durable remission in newly diagnosed MM patients in a frontline setting. However, the small sample sizes necessitate further trials with large patient populations to enhance our understanding of these outcomes with CAR-T cell therapy in MM."

CAR T-Cell Therapy • Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Neutropenia

Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study (ASH 2025) - "Novel BCMA-targeted therapies, such as CAR T-cells (cilta-cel from 2nd line, ide-cel from 3rd line) and bispecific T-cell engagers (e.g., teclistamab, elranatamab from 4th line), have become new standards of care...Abbreviations: K=carfilzomib; E=elotuzumab; Pom=pomalidomide; d=dexamethasone; Isa=isatuximab; F=panobinostat; R=lenalidomide; Tec=teclistamab; X=selinexor; Elra=elranatamab; Belamaf=belantamab mafodotin; Ixa=ixazomib... This real-world study of 100 MM patients relapsing after anti-BCMA CAR T-cell treatment shows that 91% were in their 4th or 5th line of therapy. A large majority were triple-class exposed, and 52% were lenalidomide-refractory. In the absence of a clear standard of care, common treatments were identified: elotuzumab- and isatuximab-based regimens in the 3rd line; teclistamab and elotuzumab-based options in the 4th line; and teclistamab, elranatamab, and belantamab mafodotin in the 5th line."

CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Hematological Malignancies • Hypertension • Metabolic Disorders • Multiple Myeloma • Renal Disease

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment exposure patterns indicated a heavily pretreated, triple-class refractory population: proteasome inhibitors (bortezomib 61%, carfilzomib 47%), IMiDs (lenalidomide 67%, pomalidomide 69%), and anti-CD38 monoclonal antibodies (daratumumab 67%). Additional therapies included CAR T-cell therapy (8%), autologous stem cell transplant (23%), Belantamab mafodotin (8%), Talquetamab (10%), and Teclistamab (8%)...Tocilizumab was used in 21% of patients... In comparison to the MagnetisMM-3 trial, this real-world analysis confirms the manageable immune toxicity profile of ELRA, with similarly low rates of grade ≥3 CRS and ICANS. However, the higher 6-month mortality (22.6%) observed in this cohort may reflect broader patient inclusion, including those with significant comorbidities and prior BCMA-directed therapies. Hematologic and infectious toxicities were substantial, reinforcing the need for enhanced monitoring and supportive care strategies in routine clinical use."

Real-world • Real-world evidence • Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Multiple Myeloma • Nephrology • Neutropenia • Plasma Cell Leukemia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment patterns reflected a triple-class refractory population, with high prior exposure to proteasome inhibitors (bortezomib 52%, carfilzomib 48%), IMiDs (lenalidomide 66%, pomalidomide 63%), and anti-CD38 antibodies (daratumumab 51%). Additionally, 35% had received CAR T-cell therapy, 39% underwent ASCT, 24% were treated with Teclistamab, and extramedullary disease and plasma cell leukemia were reported in 11% and 13% of patients, respectively...Grade ≥3 CRS and ICANS occurred in <10 patients each (2.4%), and 24% received tocilizumab for CRS... In this large, real-world cohort, Talquetamab demonstrated favorable short-term survival and a manageable safety profile, consistent with clinical trial data. The higher mortality observed may reflect the heavily pretreated, triple-class refractory population with advanced disease features and comorbidities often seen in real-world settings. Hematologic toxicities remained significant, while lower observed rates of..."

Real-world • Real-world evidence • Retrospective data • Dermatology • Multiple Myeloma • Neutropenia • Plasma Cell Leukemia • Thrombocytopenia

A single-center retrospective study of ixazomib-based regimens as maintenance therapy in newly diagnosed multiple myeloma (ASH 2025) - "Induction regimens included VRd (bortezomib-lenalidomide-dexamethasone, 57.4%), DVRd (daratumumab-bortezomib-lenalidomide-dexamethasone, 22.2%), and DVd (daratumumab-lenalidomide-dexamethasone, 9.3%). Notably, it effectively mitigates the adverse impact of high-risk genetic factors, positioning it as an emerging therapeutic option for high-risk NDMM maintenance therapy. Longer follow-up is warranted to confirm sustained survival benefits."

Retrospective data • Cardiovascular • Hematological Disorders • Hematological Malignancies • Hypertension • Multiple Myeloma • Thrombocytopenia

Preliminary analysis of a single-center study on chidamide combined with ICD regimen in bortezomib-exposed relapsed/refractory multiple myeloma patients (ASH 2025) - P2 | "Thus, we aimed to evaluate the efficacy and safety of chidamide combined with the ICD regimen (ixazomib, cyclophosphamide, dexamethasone) in RRMM patients exposed to bortezomib...All patients had received a median of 2 prior lines (range: 1–6), with 100% exposed to bortezomib and 90.9% to lenalidomide, 18.2% to ixazomib, 18.2% to carfilzomib, and 18.2% to daratumumab... Preliminary results demonstrate promising clinical efficacy and manageable safety of chidamide combined with ICD in RRMM patients double-exposed to bortezomib and lenalidomide. Further validation with larger cohorts and longer follow-up is warranted."

Clinical • Hematological Malignancies • Hepatology • Infectious Disease • Liver Failure • Multiple Myeloma • Pneumonia • Respiratory Diseases

Dara-RVD in newly diagnosed multiple myeloma: Real-world clinical practice (ASH 2025) - "Depending on post-ASCT MRD status, patients received lenalidomide maintenance therapy, if MRD negativity was achieved...Antitumor treatment was administered alongside supportive therapy (sulfamethoxazole-trimethoprim, acyclovir), immunoglobulin infusions, osteomodifying agents...Seven patients underwent stem cell harvesting (etoposide 750 mg/m 2 )combined with short-acting filgrastim without routine plerixafor administration...Conclusion : In the context of limited access to CAR T-cell and bispecific therapies in Russia, early use of Dara-RVd with MRD-adaptive strategies shows high efficacy, including high-risk NDMM patients. This quadruplet-based approach may shift the treatment paradigm, though careful monitoring for complications like hypogammaglobulinemia is essential."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Musculoskeletal Pain • Pneumococcal Infections • Renal Disease • Respiratory Diseases • CD34 • CTCs

Safety and efficacy of daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) in patients with multiple myeloma: A systematic review and meta-analysis. (ASH 2025) - "However, this benefit comes with an increased risk of grade 3–4 neutropenia and thrombocytopenia. No significant differences were observed in complete response or grade 3–4 anemia."

Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Dara-vd vs vrd: A breakthrough in newly diagnosed multiple myeloma treatment — superior survival and safety profiles (ASH 2025) - P=N/A | "Bortezomib, lenalidomide, and dexamethasone (VRd) is currently a standard option, but it has certain limitations, including limited efficacy in high-risk patients, significant side effects, and restricted applicability in elderly or frail patients. Peripheral edema(1.03% vs 0.93%) and pneumonia rates(4.12% vs 4.67%) were similar. In conclusion, Dara-Vd may be superior to VRd in NDMM, particularly in older patients and those with renal insufficiency, offering favorable deep remission, better PFS trends, and manageable safety."

Clinical • Cardiovascular • Geriatric Disorders • Herpes Zoster • Infectious Disease • Multiple Myeloma • Nephrology • Neutropenia • Pneumonia • Renal Disease • Respiratory Diseases • Thrombocytopenia • Thrombosis • Varicella Zoster